PannTheraPi

📍 Nîmes, France🗓 Founded 2021👥 10 employees💰 Last funded Mar 2023
Pharmaceutical Manufacturing🌐 panntehrapi.com
Website LinkedIn
PannTheraPi is the first pharmaceutical company dedicated to the development of Pannexin 1 channel blocker drugs for the treatment of brain and nervous diseases, aiming for better efficacy and better tolerance than current drugs. PannTheraPi offers breakthrough innovation for the two main issues in development of current drugs in neurological diseases: - Innovative target adressing the root cause of the diseases - Representative non-clinical model using human brain tissues PanTheraPi generates repurposed and new chemical entities drugs.
3
Total investors
3
Early stage
0
Mid stage
0
Late stage
2021
Founded

Investors

3 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
France
2
Spain
1
Frequently asked questions
Who invested in PannTheraPi?
PannTheraPi has 3 investors on record on gritt.io, including 3 early-stage backers.
When did PannTheraPi last raise funding?
The most recent investment in PannTheraPi recorded on gritt.io was in March 2023.
When was PannTheraPi founded?
PannTheraPi was founded in 2021.
What industry is PannTheraPi in?
PannTheraPi operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is PannTheraPi based?
PannTheraPi is headquartered in Nîmes, France.